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Provider Information: Influenza VISs 
 
Thirteen influenza vaccine products are approved for use in the United States for the  
2014-15 influenza season: 
 
Name Manufacturer Age Range # of Strains 
Afluria bioCSL 9 years and older* Trivalent 
Fluarix GSK 3 years and older 
Flublok Protein Sciences 18 – 49 years Trivalent 
Flucelvax Novartis 18 years and older Trivalent 
FluLaval GSK 3 years and older 
Trivalent 
Quadrivalent 
FluMist Medimmune 2 – 49 years Quadrivalent 
Fluvirin Novartis 4 years and older Trivalent 
Fluzone Sanofi Pasteur 6 months and older Trivalent 
Quadrivalent 
Fluzone High-Dose Sanofi Pasteur 65 years  and older Trivalent 
Fluzone Intradermal Sanofi Pasteur 18 – 64 years Trivalent 
 
*Afluria is licensed for ages 5 and older, but ACIP recommends that it not be used in children 5 through 8 years of age because of increased 
reports of febrile reactions in this age group.  If no other age-appropriate, inactivated influenza vaccine is available for a child 5 through 8 years 
of age who has a medical condition that increases the risk for influenza complications, Afluria can be used. However, providers should first 
discuss the benefits and risks of vaccination with Afluria with the child’s parent or caregiver. Afluria may be used in persons 9 years of age and 
older. 
 
Influenza Virus Strains in the 2014-2015 Vaccines 
 
Trivalent formulations will contain these strains: 
 A/California/7/2009 (H1N1)-like 
 A/Texas/50/2012 (H3N2)-like 
 B/Massachusetts/2/2012-like (Yamagata lineage) 
 
Quadrivalent formulations will also include: 
 B/Brisbane/60/2008-like (Victoria lineage) 
 
These are the same strains as those in the 2013-14 vaccines. 
 
 
Abbreviations used for influenza vaccines 
 
 IIV: Inactivated Influenza Vaccine (Afluria, Fluarix, FluLaval, Fluvirin, Fluzone) 
      (IIV3 = Trivalent IIV; IIV4 = Quadrivalent IIV) 
 LAIV4 (Quadrivalent): Live, Attenuated Influenza Vaccine (FluMist) 
 RIV3: Recombinant Influenza Vaccine, Trivalent (Flublok) 
 ccIIV3: Cell Culture Inactivated Influenza Vaccine, Trivalent (Flucelvax) 
 
[Note: For simplicity’s sake, IIV3, IIV4, RIV3 and ccIIV3 will be referred to collectively as IIV in this document.] 
 
Concurrent Administration  
 





New for 2014-15: LAIV Preferred for Healthy Children 2 through 8 Years of Age  
 
• If you have LAIV on hand, CDC recommends that it be used for healthy children 2 
through 8 years of age who have no contraindications or precautions. 
 
This recommendation is based on several studies that have demonstrated superior 
efficacy of LAIV in children. 
 
• If LAIV is not immediately available, IIV should be used. Vaccination should not be 
delayed in order to get LAIV. Both LAIV and IIV are safe and effective. 
 
  
People at Highest Risk for Influenza Complications & Their Close Contacts 
 
Influenza vaccination is recommended for everyone 6 months of age and older.  However, it is 
most important for people at risk for complications from influenza infection, and for people who 
care for them.  In the event of limited vaccine supply, vaccination efforts should focus on 
vaccinating these groups: 
 
 People at Highest Risk for Influenza Complications 
• all children 6 through 59 months of age, 
• all persons 50 years of age and older, 
• anyone with chronic pulmonary (including asthma) or cardiovascular (except isolated 
hypertension), renal, hepatic, neurological, hematologic, or metabolic disorders 
(including diabetes mellitus), 
• persons who have immunosuppression, including immunosuppression caused by 
medications or HIV infection, 
• women who are or will be pregnant during the influenza season, 
• children and adolescents (6 months through 18 years) who are receiving long-term aspirin 
therapy and who might be at risk for experiencing Reye’s syndrome after influenza virus 
infection, 
• residents of nursing homes and other long-term care facilities, 
• American Indians and Alaska Natives, 
• persons who are morbidly obese (BMI >40). 
 
 People who Live With or Care for Those at Highest Risk 
• healthcare personnel, 
• household contacts (including children) and caregivers of children younger than 5 years 
(i.e., prior to the 5th birthday) and adults 50 years of age and older – particular emphasis 
on vaccinating contacts of children younger than 6 months, 
• household contacts (including children) and caregivers of persons with medical 








Vaccinating Children 6 Months through 8 Years of Age 
 
Children 6 months through 8 years of age should receive two doses of influenza vaccine the first 
year they are vaccinated. Some children in this age group who have been vaccinated previously 
will also need two doses.  
 
Use either this algorithm or the alternative approach below* to determine whether a patient 6 





















*As an alternative, you may use the following approach for children whose vaccination history 
before July 1, 2010 is known: 
 
 Administer 1 dose of flu vaccine during the 2014-15 influenza season to a child 6 months 
through 8 years of age who received: 
 
- At least 1 dose of 2013-14 influenza vaccine, 
 
   
 
OR 
 - 2 or more doses of seasonal influenza vaccine since July 1, 2010, 
 
    
 
OR 
- 2 or more doses of seasonal influenza vaccine before July 1, 2010 and 1 or more doses of  
 monovalent 2009(H1N1) vaccine,  
 
    
 
OR 
 - 1 or more doses of seasonal influenza vaccine before July 1, 2010 and 1 or more doses of  
 seasonal influenza vaccine since July 1, 2010.  
 
  A child in this age group who does not meet any of these conditions should receive 2 doses 
in 2014-15, at least 4 weeks apart. 
 
Contraindications and Precautions 
 




• Guillain Barré Syndrome (GBS) 
As a precaution, persons who are not at high risk for severe influenza complications and 
who are known to have experienced GBS within 6 weeks of an influenza vaccine 
generally should not be vaccinated. As an alternative, physicians might consider using 
influenza antiviral chemoprophylaxis for these persons. The benefits of influenza 
vaccination might outweigh the risks for many persons who have a history of GBS and 
who also are at high risk for severe complications from influenza.  
The number of new cases of GBS among the general population is low. But, people with 
a history of GBS have a much higher chance of experiencing GBS than people with no 
history of the disease. It isn't known whether the flu vaccine itself might increase the risk 
of GBS returning in people who have had GBS in the past.  
 
 
• Acute Illness 
 
“The presence of a moderate or severe acute illness with or without a fever is a 
precaution to administration of all vaccines.” (ACIP General Recommendations on 
Immunization, p. 11)  The definition of “moderate or severe acute illness” is left to the 
clinical judgment of the provider.  A vaccination deferred because of an acute illness 
should be rescheduled after the illness has resolved. 
 
 
• Severe Allergy to Vaccine Component / Allergic Reaction after Previous Dose 
 
A history of a severe allergic reaction (e.g., anaphylaxis) after a previous dose of any 
influenza vaccine, or to any component of the vaccine being given is a contraindication 
for that vaccine.   
 
If a patient reports a severe allergy to any substance, it may be cross-checked against the 
contents listed on the manufacturer’s package insert, or on the following table. 
 
(NOTE: Some patients have expressed a concern that any antibiotic allergy can be a reason to 
avoid influenza vaccination. Patients should be reassured that only a rare life-threatening allergy 
to a substance is cause for concern, and that the vast majority of allergies, including allergies to 
antibiotics, are too mild to cause a vaccine to be withheld. Some influenza vaccines contain 
gentamycin, neomycin, and/or polymyxin, but many influenza vaccines do not contain any 
antibiotic.  See table below. ) 
 
  Substances shown on this table include those removed following production, for which 
only a trace remains. If in doubt, check the package insert accompanying the vaccine you 
are using. 
 
Patients are unlikely to be aware of allergies to many of these substances.  They are more 




Eggs.  All influenza vaccines, with the exception of FluBlok, contain egg protein. 
See the following section for special instructions for vaccinating egg-allergic 
patients. 
 
Antibiotics, gelatin or latex.  Because these are more commonly recognized 
allergies, they are highlighted on this table for your convenience.  
 
Vaccine Contents Latex? 
Afluria 
beta-propiolactone, thimerosol (multi-dose vials 
only), monobasic sodium phosphate, dibasic 
sodium phosphate, monobasic potassium 
phosphate, potassium chloride, calcium chloride, 
sodium taurodeoxycholate, neomycin sulfate, 
polymyxin B, ovalbumin, sodium chloride 
No August 2014 
Fluarix 
octoxynol-10 (Triton X-100), α-tocopheryl 
hydrogen succinate, polysorbate 80 (Tween 80), 
hydrocortisone, gentamicin sulfate, ovalbumin, 
formaldehyde, sodium deoxycholate, sucrose, 
phosphate buffer 
No June 2014 
Flublok 
monobasic sodium phosphate, dibasic sodium 
phosphate, polysorbate 20, baculovirus and host 
cell proteins, baculovirus and cellular DNA, Triton 
X-100, lipids, vitamins, amino acids, mineral salts 
No March 2014 
Flucelvax 
Madin Darby Canine Kidney (MDCK) cell protein, 
protein other than hemagglutinin, MDCK cell 
DNA, polysorbate 80, cetyltrimethlyammonium 
bromide, phosphate buffer, β-propiolactone 
Yes (Syringe  
tip cap) March 2014 
Fluvirin 
nonylphenol ethoxylate, thimerosal (multidose 
vial–trace only in prefilled syringe), polymyxin, 
neomycin, beta-propiolactone, ovalbumin, 
phosphate buffer 





thimerosal (multi-dose vial only), formaldehyde, 
sodium deoxycholate, ovalbumin, phosphate 




formaldehyde, octylphenol ethoxylate (Triton X-
100),  gelatin (standard trivalent formulation 
only), thimerosal (multi-dose vial only) , 
ovalbumin, phosphate buffers, sucrose 
No 2014 
FluMist 
ethylene diamine tetraacetic acid (EDTA), 
monosodium glutamate, hydrolyzed porcine 
gelatin, arginine, sucrose, dibasic potassium 
phosphate, monobasic potassium phosphate, 
gentamicin sulfate, ovalbumin 









• Egg Allergy 
 





















*Persons with egg allergy may tolerate egg in baked products (e.g. bread or cake).  Tolerance to egg-
containing foods does not exclude the possibility of egg allergy. 
† For persons who have no known history of exposure to egg, but who are suspected of being egg-allergic 
on the basis of previously performed allergy testing, consultation with a physician with expertise in the 
management of allergic conditions should be obtained prior to vaccination. Alternatively, RIV3 may be 
administered if the recipient is 18 through 49 years of age. 
   
   
   
LAIV:  






allergy, anyone with a history of egg allergy should receive IIV or RIV rather than LAIV. 












Anyone with contraindications listed in the package insert: 
 Children aged 2 through 17 years who are receiving aspirin or aspirin-
containing products.  
 Persons who have experienced severe allergic reactions to the vaccine or 






Persons with a history of egg allergy. 
 
Children aged 2 through 4 years who have asthma or who have had a wheezing 
episode noted in the medical record within the past 12 months, or for whom 
parents report that a health care provider stated that they had wheezing or asthma 
within the last 12 months.  
 
Persons who have taken influenza antiviral medications within the previous 48 







Persons of any age with asthma might be at increased risk for wheezing after 
administration of LAIV.  The safety of LAIV in persons with other underlying 
medical conditions that might predispose them to complications after wild-type 
influenza infection (e.g., chronic pulmonary, cardiovascular [except isolated 
hypertension], renal, hepatic, neurologic, hematologic, or metabolic disorders 
[including diabetes mellitus]) has not been established. These conditions, in 
addition to asthma in persons 5 years of age and older, should be considered 
precautions for the use of LAIV. 
 
A person who has received an injected live vaccine (MMR, varicella, zoster, 
yellow fever) within the past 4 weeks should wait until 4 weeks have elapsed 
before receiving LAIV, to avoid potential interference between live vaccines. 
 
Because antiviral drugs reduce replication of influenza viruses, LAIV should not 
be administered until 48 hours after cessation of influenza antiviral therapy. If 
influenza antiviral medications are administered within 2 weeks after receipt of 
LAIV, the vaccine dose should be repeated 48 or more hours after the last dose of 
antiviral medication . . . with any approved vaccine formulation. 
 
Persons who care for severely immunosuppressed persons who require a 
protective environment should not receive LAIV, or should avoid contact with 
such persons for 7 days after receipt, given the theoretical risk for transmission of 
the live attenuated vaccine virus. 
Safety 
 
• Febrile Seizures 
  
An increased risk of febrile seizures (<1 per 1,000 children vaccinated) has been observed 
in children 6 months through 4 years of age who received IIV3. The risk was higher among 
children who received PCV13 during the same visit. “Taking into consideration benefits 
and risks of vaccination, no policy change was recommended for use of IIV or PCV13.”  
 
 No increased risk was observed in children older than 4 years of age after IIV3 or in 
children of any age after LAIV. 
 
During the 2010-11 flu season, an increased risk of febrile seizures (up to 9 per 1,000 
doses) was observed among young children in Australia, associated with a Southern 
Hemisphere vaccine similar to Afluria. Because of these findings, ACIP does not 
recommend Afluria for children younger than 9 years of age. 
 
 
• Deltoid Bursitis 
 
“Severe shoulder pain and reduced range of motion in the arm where a shot was given” is 
included on the IIV VIS. This potential adverse event is being added to all updated VISs 
for injected vaccines, in response to the Institute of Medicine report, Adverse Effects of 
Vaccines: Evidence and Causality (2012), which includes deltoid bursitis among 
“injection-related adverse events.”  A study reporting 13 cases, and three VAERS reports 
were considered. The report concluded that, “the evidence convincingly supports a causal 
relationship between the injection of a vaccine and deltoid bursitis.”  Note that this 
adverse event is associated with injection, and not specifically with influenza vaccine. 
The complete report can be found at http://books.nap.edu/catalog.php?record_id=13164, 
pages 618-20.  
 
 






The 1976 swine flu vaccine was associated with increased frequency of GBS (about 1 
additional case per 100,000 persons vaccinated). 
Influenza vaccines since then have not been clearly associated with GBS. Worst-case 
estimates from the few studies that suggest an association between IIV and GBS are low 
(approximately 1 additional case per million persons vaccinated). GBS has also been 
noted to occur in relation to influenza illness.   
 








Thimerosal, a mercury-containing antibacterial compound, is used in multidose vials of 
IIV to reduce the likelihood of bacterial growth.  LAIV, RIV, and most single-dose vials 
or syringes of IIV are thimerosal-free.  Accumulating evidence shows no increased risks 
from exposure to thimerosal-containing vaccines. Persons recommended to receive IIV 





• Risk of Getting Influenza from the Vaccine 
IIV/RIV 
Vaccines that do not contain live influenza virus cannot cause influenza disease. 
 
LAIV 
The influenza virus in LAIV is “cold adapted” and “heat sensitive.” That is, it has been 
engineered to replicate in the relatively lower temperatures of the nasopharynx, but not in 
the relatively higher temperatures of the lungs. It does not cause influenza disease in 
recipients. 
People vaccinated with LAIV can shed vaccine viruses and, rarely, these viruses can be 
transmitted to unvaccinated persons. However, serious illnesses have not been reported 





While IIV is indicated for pregnant women, several manufacturers maintain registries to collect 
data on pregnancy outcomes and newborn health status from women who receive influenza 
vaccine while pregnant.  Women who receive the following vaccines while pregnant, or their 
healthcare providers, should be encouraged to contact the appropriate pregnancy registry:  
 
 Fluarix (including quadrivalent): 1-888-452-9622 
 Flublok: 1-888-855-7871 
 Flulaval (including quadrivalent): 1-888-452-9622 
 Fluzone Quadrivalent or Fluzone Intradermal: 1-800-822-2463 
 
 
For more information: 
More complete and detailed information can be found in the following publications, from which 
information in this document is predominantly derived:  
CDC. Prevention and Control of Seasonal Influenza with Vaccines. Recommendations of the Advisory 




CDC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory 
Committee on Immunization Practices (ACIP) – United States, 2014-15 Influenza Season. MMWR 2014;63 
(No. 32), 691-97.  http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6332a3.htm 
• 
September 2014 
CDC. General Recommendations on Immunization – Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR 2011;60 (No. RR-2). http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf 
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